Hepalatide clinical trials
Also written L47.
How each study uses hepalatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the hepalatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2015 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Shanghai HEP Pharmaceutical Co., Ltd. (8)
Studies
Open first, then newest update. How each study uses hepalatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DNot yet recruitingPhase 3Shanghai HEP Pharmaceutical Co., Ltd.NCT07309380Written as Hepalatide 2.1mg
- A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis DCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT06505928Written as hepalatide
- A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis BCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT04426968Written as Hepalatide 2.1mg
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B PatientsCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT05244057Written as Hepalatide
- Study of Hepalatide in Chronic Hepatitis D(CHD) PatientsCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT05827146Written as Hepalatide
- A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable MetforminWithdrawnPhase 1/2Shanghai HEP Pharmaceutical Co., Ltd.NCT04662164Written as hepalatide
- Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy VolunteersCompletedPhase 1Shanghai HEP Pharmaceutical Co., Ltd.NCT02612506Written as Hepalatide
- Study of Hepalatide(L47) at Phase Ib in Healthy VolunteersCompletedPhase 1Shanghai HEP Pharmaceutical Co., Ltd.NCT03023787Written as Hepalatide